Source:http://linkedlifedata.com/resource/pubmed/id/10370218
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
1999-7-20
|
pubmed:abstractText |
The potential, as sustained release vehicles, of gels formed in situ following the oral administration of dilute aqueous solutions of a xyloglucan polysaccharide derived from tamarind seed has been assessed by in vitro and in vivo studies. Aqueous solutions of xyloglucan that had been partially degraded by beta-galactosidase to eliminate 44% of galactose residues formed rigid gels at concentrations of 1.0 and 1.5% w/w at 37 degrees C. The in vitro release of indomethacin and diltiazem from the enzyme-degraded xyloglucan gels followed root-time kinetics over a period of 5 h at 37 degrees C at pH 6.8. Plasma concentrations of indomethacin and diltiazem, after oral administration to rats of chilled 1% w/w aqueous solutions of the enzyme-degraded xyloglucan containing dissolved drug, and a suspension of indomethacin of the same concentration were compared. Constant indomethacin plasma concentrations were noted from both formulations after 2 h and were maintained over a period of at least 7 h. Bioavailability of indomethacin from xyloglucan gels formed in situ was increased approximately threefold compared with that from the suspension. The results of this study suggest the potential of the enzyme-degraded xyloglucan gels as vehicles for oral delivery of drugs.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Anti-Inflammatory Agents...,
http://linkedlifedata.com/resource/pubmed/chemical/Antihypertensive Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Delayed-Action Preparations,
http://linkedlifedata.com/resource/pubmed/chemical/Diltiazem,
http://linkedlifedata.com/resource/pubmed/chemical/Gels,
http://linkedlifedata.com/resource/pubmed/chemical/Indomethacin,
http://linkedlifedata.com/resource/pubmed/chemical/Pharmaceutical Vehicles,
http://linkedlifedata.com/resource/pubmed/chemical/Polysaccharides
|
pubmed:status |
MEDLINE
|
pubmed:month |
Apr
|
pubmed:issn |
0378-5173
|
pubmed:author | |
pubmed:copyrightInfo |
Copyright.
|
pubmed:issnType |
Print
|
pubmed:day |
30
|
pubmed:volume |
181
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
227-34
|
pubmed:dateRevised |
2010-11-18
|
pubmed:meshHeading |
pubmed-meshheading:10370218-Administration, Oral,
pubmed-meshheading:10370218-Animals,
pubmed-meshheading:10370218-Anti-Inflammatory Agents, Non-Steroidal,
pubmed-meshheading:10370218-Antihypertensive Agents,
pubmed-meshheading:10370218-Carbohydrate Sequence,
pubmed-meshheading:10370218-Delayed-Action Preparations,
pubmed-meshheading:10370218-Diltiazem,
pubmed-meshheading:10370218-Gels,
pubmed-meshheading:10370218-Hot Temperature,
pubmed-meshheading:10370218-Indomethacin,
pubmed-meshheading:10370218-Male,
pubmed-meshheading:10370218-Molecular Sequence Data,
pubmed-meshheading:10370218-Pharmaceutical Vehicles,
pubmed-meshheading:10370218-Polysaccharides,
pubmed-meshheading:10370218-Rats,
pubmed-meshheading:10370218-Rats, Wistar
|
pubmed:year |
1999
|
pubmed:articleTitle |
Thermally reversible xyloglucan gels as vehicles for oral drug delivery.
|
pubmed:affiliation |
Faculty of Pharmaceutical Sciences, Health Science University of Hokkaido, Ishikari-Tohbetsu, Hokkaido 061-02, Japan.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|